Abstract
The aim of this research is to identify, within a systematic review, aspects of quality of life (QoL) that are adversely affected in children and adolescents with neurofibromatosis (NF), and to report predictors of quality of life in this population. Published reports of original research were included if they described QoL in children and/or adolescents with NF, and met methodological quality according to a list of predefined criteria. Seven studies conducted between 2006 and 2013 met inclusion criteria. All seven studies examined patients with NF1 and reported that these patients have lower general QoL compared to population norms. Parents’ proxy ratings of QoL were generally lower than children’s self-report ratings. By parent proxy, familial NF1 was a strong protective factor for QoL, while the opposite was found by child report. By parent proxy, male sex was significantly associated with lower scores on the parental time impact of QoL. Skin-related QoL was only slightly altered in this population, vision-specific QoL was impacted only in patients with vision loss. The majority of findings regarding predictors of QoL in children with NF1 were weak, due to a lack of studies, heterogeneity of samples, and heterogeneity of measurements/predictors assessed. Future studies should examine more comprehensively the psychosocial factors affecting the NF population, especially in young patients with NF2 and schwannomatosis, who have been neglected in prior research. The use of consistent QoL measures is preferred to allow better comparison among studies and conditions. Interventions, including comprehensive mind–body treatments, are warranted to address impaired QoL in children and adolescents with NF1.
Similar content being viewed by others
References
Lu-Emerson C, Plotkin SR (2009) The Neurofibromatoses. Part 1: NF1. Rev Neurol Dis 6:E47–E53
Lu-Emerson C, Plotkin SR (2009) The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis 6:E81–E86
Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A:327–332
Antinheimo J, Sankila R, Carpen O, Pukkala E, Sainio M, Jaaskelainen J (2000) Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 54:71–76
Sestini R, Bacci C, Provenzano A, Genuardi M, Papi L (2008) Evidence of a four hit mechanism involving SMARCB1 and NF2 in schanoomatosis associated schwannomas. Hum Mutat 29(2):227–231
Jacoby LB, Jones D, David K, Kronn D, Short PM, Gusella J, MacCollin M (1997) Molecular analyses of the NF-2 tumor supresor gene in schwannomatosis. AJHG 61(7):1293–1302
Nguyen R, Dombi E, Widemann BC, Solomon J, Fuensterer C, Kluwe L, Friedman JM, Mautner VF (2012) Growth dynamics of plexiform neurofibromas: a retrospective cohort of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis. doi:10.1186/1750-1172-7-75
Vranceanu AM, Merker VL, Park E, Plotkin SR (2013) Quality of Life among adult patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: a systematic review of the literature. J Neurooncol 114(3):257–262
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097
Kuijpers T, van der Windt DA, van der Heijden GJ, Bouter LM (2004) Systematic review of prognostic cohort studies on shoulder disorders. Pain 109:420–431
Scholten-Peeters GG, Verhagen AP, Bekkering GE, van der Windt DA, Barnsley L, Oostendorp RA, Hendriks EJ (2003) Prognostic factors of whiplash-associated disorders: a systematic review of prospective cohort studies. Pain 104:303–322
Ariens GA, van Mechelen W, Bongers PM, Bouter LM, van der Wal G (2000) Physical risk factors for neck pain. Scand J Work Environ Health 26:7–19
Garwood MM, Bernacki JM, Fine KM, Hainsworth KR, Davies WH, Klein-Tasman BP. (2006) Physical, cognitive, and psychosocial predictors of functional disability and health-related quality of life in adolescents with neurofibromatosis-1. Pain Research and Treatment 2012:Article ID 975364
Oostenbrink R, Spong K, de Goede-Bolder A, Landgraf JM, Raat H, Moll HA (2007) Parental reports of health-related quality of life in young children with neurofibromatosis type 1: influence of condition specific determinants. J Pediatr 151:182–186
Avery RA, Hardy KK (2014) Vision specific quality of life in children with optic pathway gliomas. J Neurooncol 116:341–347
Wolkenstein P, Rodriguez D, Ferkal S, Gravier H, Buret V, Algans N, Simeoni MC, Bastuji-Garin S (2008) Impact of neurofibromatosis 1 upon quality of life in childhood: a cross-sectional study of 79 cases. British Journal of Dematology 160:844–848
Krab LC, Oostenbring R, de Goede-Bolder A, Aarsen FK, Elgersma Y, Moll HA (2009) Health-related quality of life in children with neurofibromatosis type 1: contribution of demographic factors, disease-related factors, and behavior. J Pediatr 154:420–425
Graf A, Landolt MA, Capone Mori A, Boltshauser E (2006) Quality of life and psychological adjustment in children and adolescents with neurofibromatosis type 1. J Pediatr 149:348–353
Spuijbroek AT, Oostenbring R, Landgraf JM, Rietveld E, de Goede-Bolder A, van Beeck EF, van Baar M, Raat H, Moll HA (2011) Health-related quality of life in preschool children in five health conditions. Qual Life Res 20:779–786
Varni JW, Seid M, Kurtin PS (2001) PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory verion 4.0 generic core scales in healthy and patient populations. Med Care 39(8):800–812
Verrips EGH, Vogels TGC, Koopman HM, Theunissen NCM, Kamphuis RP, Fekkes M, Wit JM, Verloove-Vanhorick S (2011) Meauring health-related quality of life in a child population. Eur J Pub Health 9(3):188–193
Landgraf JM, Vogel I, Oostenbrink R, van Baar ME, Raat H (2013) Parent-reported health outcomes in infants/toddlers: measurement properties and clinical validity of the ITQOL-SF47. Qual Life Res 22(3):635–646
Baars RM, Atherton CI, Koopman HM, Bullinger M, Power M (2005) The European DISABKIDS project: development of seven condition-specific modules to measure health related quality of life in children and adolescents. Health Qual Life Outcomes 3:70
Hullman SE, Ryan JL, Ramsey RR, Chaney JM, Mullins LL (2011) Measure of General Pediatric Quality of Life. Arthritis Res Care 63(S11):S420–S430
Birch EE, Cheng CS, Felius J (2007) Validity and reliability of the children’s visual function questionnaire (CVFQ). J AAPOS 11(5):473–479
Lewis-Jones MS, Finlay AY (1995) The children’s dermatology life quality index (CDLQI): intial validation and practical use. Br J Dermatol 132(6):942–949
Eiser C, Varni JW (2013) Health-related quality of life and symptom reporting: similarities and differences between children and their parents. Eur J Pediatr 172(10):1299–1304
White-Konig M, Arnaud C, Dickinson HO, Thyen U et al (2007) Determinants of child-parent agreement in quality of life reports: a european study of children with cerebral palsy. Pediatrics 120(4):804–814
Youssef NN, Langseder AL, Verga BJ, Mones RL, Rosh JR (2005) Chronic childhood constipation is associated with impaired quality of life: a case controlled study. J Ped Gastroent and Nutrition 41:56–60
Denny S, de Silva M, Fleming T, Clark T, Merry S, Ameratunga S, Milfont T, Farrant B, Fortune SA (2014) The prevalence of chronic health conditions impacting on daily functioning and the assocaition with emotional well-being among a national sample of highschool students. J Adol Health 54(4):410–415
Jamieson N, Fitzgerald D, Singh-Grewal D, Hanson CS, Craig JC, Tong A (2014) Children’s experiences of cystic fibrosis: a systematic review of qualitative studies. Pediatrics 133(6):1683–1697
Noll RB, Reiter-Putill J, Moore DB, Schorry EK, Lovell AM, Vannatta K, Gerhardt CA (2007) Social, emotional, and behavioral functioning of children with NF1. Am J Med Genet 143(19):2261–2273
Martin S, Wolters P, Baldwin A, Gillespie A, Dombi E, Walker K, Widemann B (2012) Social-emotinal functioning of children and adolescents with neurofibromatosis type 1 and plexiform neurofibromas: relationship with cognitive, disease and environmental variables. J Ped Psychol 37(7):713–724
Vranceanu AM, Merker V, Plotkin S, Park E (2014) The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis. Results from a pilot trial. J Neurooncol 120(22):3554–3561
Wolters PL, Martin S, Merker VL, Gardner KL, Hingtgen CM, Tonsgard JH, Schorry EK, Baldwin A, REiNS International Collaboration (2013) Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials. Neurology 81(21 Suppl 1):S6–S14
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vranceanu, AM., Merker, V.L., Park, E.R. et al. Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature. J Neurooncol 122, 219–228 (2015). https://doi.org/10.1007/s11060-015-1725-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-015-1725-1